2.13

3.40% 0.07

Acrivon Therapeutics Inc (ACRV)

Overview News Price History Financials Discussions Forecast

Acrivon Therapeutics Inc stock is traded at $2.13, with a volume of 184.47K. It is up +3.40% in the last 24 hours and up +36.54% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Previous Close:

$2.06

Open:

$2.06

24h Volume:

184.47K

Relative Volume:

0.44

Market Cap:

$91.28M

Revenue:

Net Income/Loss:

$-77.27M

P/E Ratio:

-1.064

EPS:

-2.0019

Net Cash Flow:

$-66.29M

1W Performance:

+3.40%

1M Performance:

+36.54%

6M Performance:

+26.04%

1Y Performance:

+63.85%

1-Day Range:

$2.055

$2.14

1-Week Range:

$2.0209

$2.20

52-Week Range:

$1.27

$3.56

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name

Acrivon Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

617-207-8979

Address

480 ARSENAL WAY, SUITE 100, WATERTOWN

Employee

Twitter

Next Earnings Date

2026-08-12

Latest SEC Filings

ACRV's Discussions on Twitter

Compare ACRV vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRV Acrivon Therapeutics Inc	2.13	94.28M	0	-77.27M	-66.29M	-2.0019
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-05-25	Resumed	Piper Sandler	Overweight
Jan-31-25	Initiated	KeyBanc Capital Markets	Overweight
Sep-16-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Apr-29-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-24	Initiated	JMP Securities	Mkt Outperform
Dec-15-23	Resumed	Jefferies	Buy
Oct-05-23	Initiated	Maxim Group	Buy
Jun-02-23	Initiated	Oppenheimer	Outperform
May-08-23	Initiated	BMO Capital Markets	Outperform
Apr-27-23	Initiated	Ladenburg Thalmann	Buy
Apr-20-23	Initiated	H.C. Wainwright	Buy
Dec-12-22	Initiated	Cowen	Outperform
Dec-12-22	Initiated	Jefferies	Buy
Dec-12-22	Initiated	Piper Sandler	Overweight

View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

Aug 20, 2026

Acrivon (ACRV) Results Breakdown: EPS Exceeds Its Estimate in the Latest Session; Post-Report: The Stock Closes Near Unchanged on the DayFull Year Guidance - vinanet.vn

Aug 19, 2026

Aug 17, 2026

ACRV Q1 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 5.9%Capex Guidance - vinanet.vn

Aug 17, 2026

Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst - MarketBeat

Aug 17, 2026

Aug 16, 2026

ACRV Q1 2026 Earnings: Loss Narrower Than Expected, Stock Advances 5.41%Forward EPS Estimate - Vinanet

Aug 16, 2026

Aug 14, 2026

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings - MarketBeat

Aug 14, 2026

Aug 13, 2026

Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Aug 13, 2026

Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan

Aug 13, 2026

Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained - TipRanks

Aug 13, 2026